TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15303783

Group type: EXPERIMENTAL
Intervention: Desonide (cream, ointment, or lotion formulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 0
Study: 11718681

Group type: EXPERIMENTAL
Intervention: Postmenopausal women
Number of subjects: 196

Group type: COMPARATOR
Intervention: CETP concentration
Number of subjects: 196
Study: 10553820

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) 40 ppm
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) 0.1 microg x kg(‐1) min(‐1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) 3 to 5 microg x kg(‐1) min(‐1)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 14
Study: 7872445

Group type: EXPERIMENTAL
Intervention: Ceftriaxone, 2 g/day for adults and 50 mg/kg/day for children, intravenously once a day for three days
Number of subjects: 46

Group type: COMPARATOR
Intervention: Chloramphenicol, 60 mg/kg/day orally four times a day until defervescence, followed by 40 mg/kg/day for a total of 14 days
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 46

Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ceftriaxone and Chloramphenicol
Number of subjects: 46
Study: 1982289

Group type: EXPERIMENTAL
Intervention: Minimal‐therapist‐involvement stress inoculation training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synchronous changes in heart rate and report of anxiety during exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Voluntary plane flights in the two months following treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flight avoiders
Number of subjects: 0
Study: 642973

Group type: EXPERIMENTAL
Intervention: Hemolytic-uremic syndrome patients with endotoxemia
Number of subjects: 241

Group type: COMPARATOR
Intervention: Uncomplicated shigellosis
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Circulating immune complexes
Number of subjects: 241
Study: 31945738

Group type: EXPERIMENTAL
Intervention: Visual feedback with a laser sensor (VFLS)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control set
Number of subjects: 19
Study: 31451913

Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g daily + 1000 mg calcium + 800 IU vitamin D (strontium group; SG)
Number of subjects: 52

Group type: COMPARATOR
Intervention: 1000 mg calcium + 800 IU vitamin D (placebo group; PG)
Number of subjects: 52
Study: 28859708

Group type: EXPERIMENTAL
Intervention: PEA olfactory training
Number of subjects: 81

Group type: COMPARATOR
Intervention: Mineral oil olfactory training
Number of subjects: 81
Study: 25959549

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT) for BED
Number of subjects: 189
Study: 24147266

Group type: EXPERIMENTAL
Intervention: Aspirin continued (Group 1)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Aspirin stopped (Group 2)
Number of subjects: 150

Group type: COMPARATOR
Intervention: No aspirin (Group 3 - Control)
Number of subjects: 150
Study: 21486862

Group type: EXPERIMENTAL
Intervention: Rituximab re-treated patients (n=112)
Number of subjects: 175

Group type: COMPARATOR
Intervention: No rituximab second line (n=53)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation
Number of subjects: 175

Group type: COMPARATOR
Intervention: No autologous stem cell transplantation
Number of subjects: 175
Study: 21319007

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) 0.625 mg/day and medroxyprogesterone acetate (MPA) 2.5 mg/day
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Oral estriol (E3) 2 mg/day
Number of subjects: 34
Study: 17245174

Group type: EXPERIMENTAL
Intervention: Fenofibrate (5 mg/kg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 15767960

Group type: EXPERIMENTAL
Intervention: Endobronchial valve placement
Number of subjects: 270

Group type: COMPARATOR
Intervention: Optimal medical treatment
Number of subjects: 270
Study: 11575894

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 20
Study: 10197141

Group type: EXPERIMENTAL
Intervention: Cetirizine (20 mg, twice the daily recommended dose)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 9223914

Group type: EXPERIMENTAL
Intervention: Interferon-alpha therapy (3 x 10(6) U recombinant IFN alpha, subcutaneously three times a week, every other day, for a total of 12 doses)
Number of subjects: 5
Study: 2506965

Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 1020
Study: 1203699

Group type: EXPERIMENTAL
Intervention: Hypertonic glucose, fructose, and sorbitol solutions (IV)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 28
Study: 31838497

Group type: EXPERIMENTAL
Intervention: TE (0.1 mg/day) + IMP (200 mg/day for 12 days)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 31173128

Group type: EXPERIMENTAL
Intervention: Brief Admission (BA)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 125
Study: 29319063

Group type: EXPERIMENTAL
Intervention: Supervised Toothbrushing (STB) in Ultra-Conservative Treatment (UCT)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Conventional Restorative Treatment (CRT) with Unsupervised Toothbrushing (USTB)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Atraumatic Restorative Treatment (ART) with Unsupervised Toothbrushing (USTB)
Number of subjects: 273

Group type: COMPARATOR
Intervention: No-treatment with Unsupervised Toothbrushing (USTB)
Number of subjects: 273
Study: 25310510

Group type: EXPERIMENTAL
Intervention: Lungs from heavy alcohol users
Number of subjects: 74

Group type: COMPARATOR
Intervention: Lungs from lighter alcohol users
Number of subjects: 74
Study: 22612560

Group type: EXPERIMENTAL
Intervention: Evaluative conditioning intervention (associating thin-ideal models with synonyms of fake)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Evaluative conditioning intervention
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control condition (equivalent task without learning association)
Number of subjects: 105
Study: 22187767

Group type: EXPERIMENTAL
Intervention: palanosetron (0.25 mg) IV
Number of subjects: 75

Group type: COMPARATOR
Intervention: granisetron (3.0 mg) IV
Number of subjects: 75

Group type: COMPARATOR
Intervention: ondansetron (8.0 mg) IV
Number of subjects: 75
Study: 19332185

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke
Number of subjects: 20000
Study: 16758048

Group type: EXPERIMENTAL
Intervention: Non-stented group (45 patients)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Stented group (40 patients)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Non-stented group
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 85
Study: 14998843

Group type: EXPERIMENTAL
Intervention: Single-agent chemotherapy (gemcitabine, vinorelbine, taxanes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carboplatin-based or low-dose cisplatin-based doublets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-agent chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Platinum-based combinations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New biological agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supportive care improvements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symptomatic improvement
Number of subjects: 0
Study: 12579942

Group type: EXPERIMENTAL
Intervention: Salbutamol aerosol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral solution of salbutamol
Number of subjects: 10
Study: 9006756

Group type: EXPERIMENTAL
Intervention: Meniscus operation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Regular exercise of thigh muscles
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bandaging
Number of subjects: 50

Group type: COMPARATOR
Intervention: Repeat clinical examination
Number of subjects: 50

Group type: COMPARATOR
Intervention: Overall surgery requirement
Number of subjects: 50

Group type: COMPARATOR
Intervention: Symptoms related to patellofemoral joint or postoperative condition
Number of subjects: 50
Study: 8314287

Group type: EXPERIMENTAL
Intervention: Cefuroxime (4.05 g/die)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cefotiam (5.30 g/die)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cefotiam with furosemide (0.5 mg/kg body weight) intravenously
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cefuroxime with furosemide (0.5 mg/kg body weight) intravenously
Number of subjects: 41
Study: 3285835

Group type: EXPERIMENTAL
Intervention: 20 mg torasemide
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 100 mg torasemide
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: furosemide (60 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 46
Study: 29141548

Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT) program, conducted twice a week for six months.
Number of subjects: 140

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 140
Study: 28766500

Group type: EXPERIMENTAL
Intervention: Test formulation of memantine 10 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference formulation of memantine 10 mg
Number of subjects: 20
Study: 26140004

Group type: EXPERIMENTAL
Intervention: 4-sample lactose hydrogen breath test (4SLHBT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard 13-sample lactose hydrogen breath test (LHBT)
Number of subjects: 120
Study: 23267867

Group type: EXPERIMENTAL
Intervention: Standard group (c-RFA with device removal and cleaning)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Simple-with-cleaning group (c-RFA with device cleaning without removal)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Simple-no-cleaning group (2 applications of c-RFA, device not removed or cleaned)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Standard group
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Simple-with-cleaning group
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Simple-no-cleaning group
Number of subjects: 57

Group type: COMPARATOR
Intervention: Simple groups (both simple-with-cleaning and simple-no-cleaning)
Number of subjects: 57
Study: 21727758

Group type: EXPERIMENTAL
Intervention: Home-based bench-stepping exercise training for 18 months
Number of subjects: 189
Study: 19794994

Group type: EXPERIMENTAL
Intervention: Epidural PCA (ropivacaine 0.2% + fentanyl 5 microg/mL at 4 mL/hr)
Number of subjects: 52

Group type: COMPARATOR
Intervention: IV PCA (ketorolac 0.2 mg/kg + fentanyl 15 microg/mL at 1 mL/hr)
Number of subjects: 52
Study: 16874871

Group type: EXPERIMENTAL
Intervention: B-OAzM (omeprazole 20 mg, bismuth subcitrate 240 mg, azithromycin 250 mg, and metronidazole 500 mg, all twice daily for 1-wk)
Number of subjects: 129

Group type: COMPARATOR
Intervention: B-OAM (omeprazole 20 mg, bismuth subcitrate 240 mg, amoxicillin 1 g, and metronidazole 500 mg, all twice daily for 2-wk)
Number of subjects: 129
Study: 12775734

Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg (intermittent)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Gefitinib 500 mg (intermittent)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Gefitinib 500 mg (continuous)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Chemotherapy (carboplatin and paclitaxel)
Number of subjects: 24
Study: 10835489

Group type: EXPERIMENTAL
Intervention: Beta-carotene 30 mg/day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Vitamin C 1000 mg/day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High-dose beta-carotene
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (0 mg beta-carotene, 0 mg vitamin C)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Beta-carotene 3 mg/day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Vitamin C 50 mg/day
Number of subjects: 54
Study: 9353803

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (twice-daily treatment sessions for 3 months)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (daily retention of the control probe)
Number of subjects: 54
Study: 8384170

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (dFE: 30 mg per os)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 7
Study: 3885152

Group type: EXPERIMENTAL
Intervention: Vitamin E treatment (mean serum level 5.1 mg/dL)
Number of subjects: 914

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 914
Study: 30043917

Group type: EXPERIMENTAL
Intervention: Extended-time noninvasive positive pressure ventilation (E-NPPV)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Short-time noninvasive positive pressure ventilation (S-NPPV)
Number of subjects: 41
Study: 27212622

Group type: EXPERIMENTAL
Intervention: Adherence to nutritional recommendations for saturated fat and fiber consumption
Number of subjects: 2573

Group type: EXPERIMENTAL
Intervention: Adherence to nutritional recommendations for added sugars
Number of subjects: 2573
Study: 25543610

Group type: EXPERIMENTAL
Intervention: Selective-loading group (loaded at week 6 with 150g force)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Delay-loading group (loaded at week 12 with 150g force)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups (loading and unloading mini-implants)
Number of subjects: 14
Study: 23062766

Group type: EXPERIMENTAL
Intervention: 180 μg/d MK-7 supplementation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 360 μg/d MK-7 supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MK-7 supplementation (both doses)
Number of subjects: 60
Study: 20669650

Group type: EXPERIMENTAL
Intervention: FESS + SIT after operation
Number of subjects: 0

Group type: COMPARATOR
Intervention: FESS only
Number of subjects: 0
Study: 18562793

Group type: EXPERIMENTAL
Intervention: Postoperative delirium patients
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control patients (matched for preoperatively assessed risk factors)
Number of subjects: 112
Study: 16218396

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT‐A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 12456604

Group type: EXPERIMENTAL
Intervention: Serum AMH levels
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Baseline serum AMH concentrations
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Inclusion of inhibin B and FSH concentrations to AMH
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Post GnRH agonist rise in FSH and LH levels
Number of subjects: 130
Study: 10479120

Group type: EXPERIMENTAL
Intervention: CMV gB vaccine with MF59
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CMV gB vaccine with alum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CMV gB vaccine with MF59 (fourth dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8955652

Group type: EXPERIMENTAL
Intervention: Topotecan (TPT) administered as a 30-minute infusion daily for 5 days, with doses of 0.75 mg/m2, 1 mg/m2, and 0.75 mg/m2 in combination with cisplatin (CDDP) at doses of 50 mg/m2 and 75 mg/m2.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin (CDDP) administered either before TPT on day 1 or after TPT on day 5.
Number of subjects: 0
Study: 1837251

Group type: EXPERIMENTAL
Intervention: NaCl baths
Number of subjects: 218

Group type: COMPARATOR
Intervention: Underwater massage-showers
Number of subjects: 218
Study: 6309730

Group type: EXPERIMENTAL
Intervention: Ampicillin (500 mg, single dose)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cefaclor (500 mg, single dose)
Number of subjects: 9
Study: 31544476

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (Group MM)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Progressive relaxation meditation (Group PM)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control meditation (Group CM)
Number of subjects: 105
Study: 27939238

Group type: EXPERIMENTAL
Intervention: Exercise Referral (ER)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brief PA Counseling (BC)
Number of subjects: 0
Study: 27070434

Group type: EXPERIMENTAL
Intervention: Gabapentin (300-2700 mg daily)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 25093663

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Transversus Abdominis Plane (TAP) block (levobupivacaine = 150 mg)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Continuous Wound Infusion (CWI) (levobupivacaine = 150 mg first day and 12.5 mg/h thereafter)
Number of subjects: 65
Study: 22928872

Group type: EXPERIMENTAL
Intervention: Exercise intervention (three weekly physical exercise sessions lasting 60-75 minutes each for 16 weeks)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 150
Study: 20071838

Group type: EXPERIMENTAL
Intervention: Lidocaine 1% infiltration (20 ml)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No infiltration (Control Group)
Number of subjects: 120
Study: 17884597

Group type: EXPERIMENTAL
Intervention: Standard Gamble (SG)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Time Trade-Off (TTO)
Number of subjects: 96
Study: 16180047

Group type: EXPERIMENTAL
Intervention: Lichtenstein technique (LH) using polypropylene mesh
Number of subjects: 32

Group type: COMPARATOR
Intervention: Bassini open conventional hernia repair (BH)
Number of subjects: 32
Study: 12153805

Group type: EXPERIMENTAL
Intervention: Fourier transform‐based spectral retinal imaging (SRI)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fluorescein angiography
Number of subjects: 10
Study: 10492263

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP), 220 microg bid
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP), 88 microg plus salmeterol (SL), 42 microg bid
Number of subjects: 680

Group type: COMPARATOR
Intervention: Triamcinolone acetonide (TAA), 600 microg bid
Number of subjects: 680
Study: 8584192

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.005 mg/kg + Midazolam 0.2 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.005 mg/kg + Propofol 2.5 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg + Propofol 2.0 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fentanyl-Propofol association
Number of subjects: 40
Study: 1852093

Group type: EXPERIMENTAL
Intervention: Psyllium fiber
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 6113127

Group type: EXPERIMENTAL
Intervention: Lormetazepam (1 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diazepam (5 mg)
Number of subjects: 100
Study: 31977046

Group type: EXPERIMENTAL
Intervention: INSTI-based triple regimen given 4D a week
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: INSTI-based triple regimen given 5D a week
Number of subjects: 73
Study: 31537562

Group type: EXPERIMENTAL
Intervention: Chest radiograph (CXR) every 3 months for 2 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chest radiograph (CXR) every 6 months for 2 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chest CT every 3 months for 2 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chest CT every 6 months for 2 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall survival (primary outcome of the definitive trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes on anxiety, satisfaction, and quality of life
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local recurrence-free survival
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metastasis-free survival
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment-related complications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Net healthcare costs related to surveillance
Number of subjects: 0
Study: 27908546

Group type: EXPERIMENTAL
Intervention: BCAA supplementation (Aminoleban EN)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Diet alone (control group)
Number of subjects: 51
Study: 25890211

Group type: EXPERIMENTAL
Intervention: Rupatadine (10 mg, 20 mg, 40 mg single doses; 10 mg multiple doses)
Number of subjects: 0
Study: 23579010

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy with Defibrillator (CRT-D)
Number of subjects: 1076

Group type: COMPARATOR
Intervention: Implantable Cardioverter-Defibrillator (ICD)
Number of subjects: 1076
Study: 22314633

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM) 5 g twice daily, n = 22
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Acupuncture plus CHM (Kun Bao Wan) 5 g twice daily plus sessions of acupuncture, n = 20
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Hormone therapy, n = 15
Number of subjects: 57
Study: 19032447

Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride (300 mg/day)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium (20 mg/day)
Number of subjects: 7
Study: 16434068

Group type: EXPERIMENTAL
Intervention: Cherry Kool Aid sweetened with 20% sucrose
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cherry Kool Aid sweetened with 10% sucrose
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cherry Kool Aid sweetened with 5% sucrose
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cherry Kool Aid sweetened with 2.5% sucrose
Number of subjects: 9

Group type: COMPARATOR
Intervention: Cherry Kool Aid unsweetened
Number of subjects: 9
Study: 12604982

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG) 10^9 orally twice daily for 21 days in infants <1500 g
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG) for 8 days in infants 1500 to 1999 g
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no LGG treatment) for infants <1500 g
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no LGG treatment) for infants 1500 to 1999 g
Number of subjects: 71